Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2020 10:47 ET | Source: Chiesi USA, Inc.

Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice-a-day tablets

BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today...
April 24, 2020 08:00 ET | Source: Chiesi USA, Inc.

Chiesi Global Rare Diseases Recognizes Fabry Disease Awareness Month and Launches “Fabry Focus on Health” Educational Series to Support Patients and Caregivers During COVID-19 Pandemic

Program offers suggestions from leading clinicians and other experts regarding impact of COVID-19 on families affected by Fabry disease BOSTON, April 24, 2020 (GLOBE NEWSWIRE) -- Chiesi Global...
March 31, 2020 09:00 ET | Source: Chiesi USA, Inc.

Chiesi USA increases support measures for employees, patients and community partners in response to COVID-19 pandemic

Chiesi USA implemented increased health and well-being measures to support employees.Chiesi’s production line and supply chain are operating with no disruption across the network.Chiesi USA has...
March 02, 2020 09:00 ET | Source: Chiesi USA, Inc.

Chiesi USA certified as a Great Place to Work® in 2019

CARY, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, has earned the Great Place to Work® Certification for 2019 in the U.S. The...
February 27, 2020 08:00 ET | Source: Chiesi USA, Inc.

Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020

Chiesi Group recently announced launch of new Chiesi Global Rare Diseases division to address significant unmet needs in rare diseasesDivision to advance research and build partnership opportunities...
February 26, 2020 09:00 ET | Source: Chiesi USA, Inc.

Chiesi in the Community donates nearly $1 million in 2019

Chiesi’s CSR program increases contributions to the Triangle community and therapeutic areas CARY, N.C., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee) contributed more than...
February 06, 2020 07:00 ET | Source: Chiesi USA, Inc.

Chiesi Group Announces Establishment of New Global Rare Diseases Division

Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patientsChiesi Global Rare Diseases...
January 30, 2020 08:30 ET | Source: Chiesi USA, Inc.

Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2020

CARY, N.C., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee) announced today that the company has been named as a Top Employer in the United States for the fifth consecutive year. The...
January 13, 2020 08:30 ET | Source: Chiesi USA, Inc.

Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)

Chiesi Group expands distribution network via acquisition for worldwide product rights.Chiesi Group will establish offices in Toronto, Canada. PARMA, Italy, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiesi...
October 01, 2019 11:41 ET | Source: Chiesi USA, Inc.

Single-Inhaler Extrafine Triple Therapy of Inhaled Corticosteroid, Long-Acting B2-Agonist and Long-Acting Muscarinic Antagonist Therapy Improves Lung Function and Reduces Asthma Exacerbations(1)

Data from two randomized, double-blind, parallel-group, active-controlled studies on the efficacy and safety of single-inhaler triple therapy in adult patients with uncontrolled asthma is published in...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right